PBC

FINN Partners and Humble Ventures 'Future of Health' Summit Returns to Austin on Saturday, March 9 at The Cathedral

Retrieved on: 
Friday, March 1, 2024
ARPA, Pioneer, Urban Institute, OSTP, Cathedral, Mental, PBC, HHS, Technology policy, House, Maternal health, Potential, Nursing

NEW YORK, March 1, 2024 /PRNewswire/ -- FINN Partners, a global independent marketing and communications agency, and Humble Ventures, a venture capital and private equity firm focused on diverse founders, entrepreneurs, start-ups and organizations, are joining forces for the second year in a row to host the FINNxHumble House 2024 in Austin—an unparalleled event bringing together the global community of innovators, disruptors, visionaries and activists across health, technology, government and entertainment to forge connections and explore solutions to drive equity and connectivity across the fragmented heath ecosystem and beyond.

Key Points: 
  • WHERE: The Cathedral , 2403 E. 16th St., Austin, Texas 78702
    REGISTER TO RESERVE A SPOT: https://lu.ma/50aw5x77
    FINNxHumble House is the central destination for those who are pioneering ideas and partnerships to fix the broken health ecosystem, improve patient care and explore new horizons.
  • Highlights include:
    Bridging the Gaps in Maternal Health with GE Healthcare Foundation, Urban Institute and Lwala Community Alliance
    The Pioneers of Innovation in Women's Health with ServiceNow Ventures, Gabbi, Betty's Co and Marani Health
    Leveraging Health Technology to Close Care Gaps in Rural Communities with Zorya Foundation, Best Buy Health, Addictions Research Institute and ARPA-H
    Beyond the Brain: Exploring the Potential of Neurotech Solutions for Mental & Physical Health with Corundum Neuroscience, Sanmai Technologies PBC, PsyMed Ventures and Cognixion
    Whitehouse-led Innovation with Stephen Konya and a delegation from the U.S. Department of Health and Human Services (HHS), White House Office of Science and Technology Policy (OSTP) and others, sharing top priorities and collaboration opportunities
    Following the panel programming, FINNxHumble will host a #HumbleHang, featuring live music by local Austin bands, interactive trivia and more.
  • Limited spots for the FINNxHumble Future of Health Summit.
  • Register now: https://lu.ma/50aw5x77 .

CARLA TULLY APPOINTED TO NIKOLA BOARD OF DIRECTORS

Retrieved on: 
Friday, February 16, 2024
The, AES, MAP, AES Corporation, University, Tufts University, Earthrise, Strategic management, Transport, Growth, Columbia Business School, CSR, Female, MBA, PBC, Entrepreneurship, Corporate responsibility, Bachelor, Citizenship, Creativity, Nikola Corporation, Economics, HYLA, Diplomacy, Management

PHOENIX, Feb. 16, 2024 /PRNewswire/ -- Nikola Corporation (Nasdaq: NKLA), a global leader in zero-emissions transportation and energy supply and infrastructure solutions, via the HYLA brand, today announced the appointment of energy and infrastructure expert Carla Tully, to its Board of Directors. Over more than two decades, Tully has built a successful track record leading and scaling energy organizations across Fortune 150, private equity, startup, and government entities. Tully serves as the Vice Chair of Earthrise Energy's Board of Directors, a Board Director for Citizens for Responsible Energy Solutions Forum and as an Advisor to several energy transition startups.

Key Points: 
  • PHOENIX, Feb. 16, 2024 /PRNewswire/ -- Nikola Corporation (Nasdaq: NKLA), a global leader in zero-emissions transportation and energy supply and infrastructure solutions, via the HYLA brand , today announced the appointment of energy and infrastructure expert Carla Tully, to its Board of Directors .
  • Tully serves as the Vice Chair of Earthrise Energy's Board of Directors, a Board Director for Citizens for Responsible Energy Solutions Forum and as an Advisor to several energy transition startups.
  • "As Nikola scales its energy infrastructure business, especially in the hydrogen ecosystem, the addition of Carla to Nikola's Board of Directors will greatly benefit our company, employees and shareholders," said Steve Shindler, Chairman of Nikola's Board of Directors.
  • I've dedicated my career to similar missions, and I am delighted to join Nikola's Board of Directors and support Nikola in 2024 and beyond."

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance

Retrieved on: 
Thursday, February 15, 2024
Managed Care, Biotechnology, Pharmaceutical, Health, Acquisition, Liver, Autoimmune disease, Income tax, Hepatology, FDA, Food, Endometriosis, PBC, Interest expense, Constipation, Annual general meeting, Short bowel syndrome, Safety, Society, GAAP, The Lancet, UEG, Pharmacokinetics, Food and Drug Administration, Primary biliary cholangitis, Interest, Patient, Disease, STARS, Phase, Interstitial cystitis, Trial of the century, Ageing, United European Gastroenterology, CIC, Research, SBS, Depreciation, Video game

Total revenues in the fourth quarter of 2023 were $117.6 million, compared to $107.2 million in the fourth quarter of 2022.

Key Points: 
  • Total revenues in the fourth quarter of 2023 were $117.6 million, compared to $107.2 million in the fourth quarter of 2022.
  • Operating expenses in the fourth quarter of 2023 were $80.0 million, compared to $38.8 million in the fourth quarter of 2022.
  • Adjusted EBITDA was $39.9 million in the fourth quarter of 2023, compared to $68.7 million in the fourth quarter of 2022.
  • Ironwood generated $35.8 million in cash from operations in the fourth quarter of 2023, compared to $79.2 million in cash from operations in the fourth quarter of 2022.

Aniq Ahmad Joins Opportune as Managing Director and President of the Firm’s Outsourcing Practice

Retrieved on: 
Wednesday, February 14, 2024
Professional Services, Other Energy, Other Professional Services, Energy, Finance, Consulting, Banking, CPA, Rice University, Multimedia, EY, Transport, Growth, MBA, Targa Resources, PBC, Water, ICAP, Consultant

Opportune LLP, a leading global business advisory firm, is pleased to announce that Aniq Ahmad has joined the firm as Managing Director and President of Outsourcing.

Key Points: 
  • Opportune LLP, a leading global business advisory firm, is pleased to announce that Aniq Ahmad has joined the firm as Managing Director and President of Outsourcing.
  • Mr. Ahmad brings 20 years of energy industry experience to Opportune where his primary focus will be managing the firm’s Outsourcing practice.
  • View the full release here: https://www.businesswire.com/news/home/20240214123879/en/
    Aniq Ahmad | Opportune LLP (Photo: Business Wire)
    “Aniq brings a wealth of experience and strategic vision to Opportune,” remarked David Baggett , Managing Partner.
  • “I am thrilled to be joining Opportune, a firm renowned for its commitment to excellence and client success,” said Mr. Ahmad.

Satellite Data Services Market worth $20.9 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Wednesday, February 14, 2024
Aircraft, Unmanned aerial vehicle, Region, Mining, Strategic planning, Growth, Satellite, Government, PBC, Commercial, Environmental monitoring, L3Harris Technologies, Security, CubeSat, Global Positioning System, Geographic information system, Transport, Organic, Defense, Maxar Technologies, Robotics, Agriculture, Orbit, AWS, Cargo, Planet Labs, Remote sensing, NASA, ICEYE, Safety, Classification, Forestry, Spacecraft, Insurance, Collection, SSA, Intelligence, Internet of things, Confidentiality, Communication, GPS, Organization, Privacy, Spatial, GIS, Movement, CSDA, Communications satellite

Overcoming these challenges while capitalizing on the growing demand for satellite data services will be crucial for sustaining market growth and fostering innovation in the years ahead.

Key Points: 
  • Overcoming these challenges while capitalizing on the growing demand for satellite data services will be crucial for sustaining market growth and fostering innovation in the years ahead.
  • Based on the vertical, the Defense & Security segment is estimated to lead the Satellite Data Services Market from 2023 to 2028.
  • In 2023, the commercial segment is anticipated to dominate the Satellite Data Services market, holding the largest market share.
  • This includes high-resolution imaging sensors, small satellite constellations, and data analytics platforms, driving the growth of satellite data services in the region.

Satellite Data Services Market worth $20.9 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Wednesday, February 14, 2024
Aircraft, Unmanned aerial vehicle, Region, Mining, Strategic planning, Growth, Satellite, Government, PBC, Commercial, Environmental monitoring, L3Harris Technologies, Security, CubeSat, Global Positioning System, Geographic information system, Transport, Organic, Defense, Maxar Technologies, Robotics, Agriculture, Orbit, AWS, Cargo, Planet Labs, Remote sensing, NASA, ICEYE, Safety, Classification, Forestry, Spacecraft, Insurance, Collection, SSA, Intelligence, Internet of things, Confidentiality, Communication, GPS, Organization, Privacy, Spatial, GIS, Movement, CSDA, Communications satellite

Overcoming these challenges while capitalizing on the growing demand for satellite data services will be crucial for sustaining market growth and fostering innovation in the years ahead.

Key Points: 
  • Overcoming these challenges while capitalizing on the growing demand for satellite data services will be crucial for sustaining market growth and fostering innovation in the years ahead.
  • Based on the vertical, the Defense & Security segment is estimated to lead the Satellite Data Services Market from 2023 to 2028.
  • In 2023, the commercial segment is anticipated to dominate the Satellite Data Services market, holding the largest market share.
  • This includes high-resolution imaging sensors, small satellite constellations, and data analytics platforms, driving the growth of satellite data services in the region.

United Therapeutics Corporation to Report Fourth Quarter and Full Year 2023 Financial Results Before the Market Opens on Wednesday, February 21, 2024

Retrieved on: 
Wednesday, February 14, 2024
Health, Other Science, Research, Science, Pharmaceutical, Cardiology, Biotechnology, United Therapeutics, Patient, Creativity, Therapy, UTHR, Webcast, PBC, Pharmaceutical industry

United Therapeutics Corporation (Nasdaq: UTHR), announced today that it will report its fourth quarter and full year 2023 financial results before the market opens on Wednesday, February 21, 2024.

Key Points: 
  • United Therapeutics Corporation (Nasdaq: UTHR), announced today that it will report its fourth quarter and full year 2023 financial results before the market opens on Wednesday, February 21, 2024.
  • United Therapeutics will host a public webcast Wednesday, February 21, 2024, at 9:00 a.m. Eastern Time.
  • The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations .
  • We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC).

Zevia to Announce Fourth Quarter and Full Year 2023 Results on Tuesday, February 27, 2024

Retrieved on: 
Tuesday, February 13, 2024
Online Retail, Retail, Health, Fitness & Nutrition, Supermarket, Food, Beverage, PBC

Zevia PBC (“Zevia”) (NYSE:ZVIA) today announced that it will release its financial results for the fourth quarter and full year 2023 ended December 31, 2023 before the market open on Tuesday, February 27, 2024 followed by a conference call at 8:30 a.m. Eastern Time to discuss the results.

Key Points: 

Zevia PBC (“Zevia”) (NYSE:ZVIA) today announced that it will release its financial results for the fourth quarter and full year 2023 ended December 31, 2023 before the market open on Tuesday, February 27, 2024 followed by a conference call at 8:30 a.m. Eastern Time to discuss the results.

Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics

Retrieved on: 
Monday, February 12, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Hospitals, Clinical Trials, Alkaline phosphatase, EMA, Woman, Gilead Sciences, Multimedia, Liver disease, Quality of life, Ascending cholangitis, PBC, Risk, Hepatology, Cirrhosis, Seladelpar, Therapy, Fatigue, PRIME, Primary biliary cholangitis, Patient, BofA Securities, Guggenheim Partners, Itch, Centerview Partners, Lazard, Pharmaceutical industry

Gilead Sciences, Inc. (Nasdaq: GILD) and CymaBay Therapeutics, Inc. (Nasdaq: CBAY) announced today a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) and CymaBay Therapeutics, Inc. (Nasdaq: CBAY) announced today a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion.
  • View the full release here: https://www.businesswire.com/news/home/20240211034242/en/
    “We are looking forward to advancing seladelpar by leveraging Gilead’s long-standing expertise in treating and curing liver diseases,” said Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences.
  • Seladelpar is an investigational, oral, selective peroxisome proliferator-activated receptor delta (PPARδ) agonist, shown to regulate critical metabolic and liver disease pathways.
  • “Today’s agreement with Gilead is the culmination of years of focus and determination at CymaBay to advance seladelpar and bring new hope to people living with PBC and their families,” said Sujal Shah, President, and CEO at CymaBay Therapeutics.

CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis

Retrieved on: 
Monday, February 12, 2024
Alkaline phosphatase, Liver, Child, Ursodeoxycholic acid, New Drug Application, BTD, Cirrhosis, Inflammation, FDA, Quality of life, Food, Breakthrough, Chief, Conditional sentence, PDUFA, ALP, PBC, Seladelpar, Therapy, Fatigue, Patient, Itch, Mortality, NDA, Pharmaceutical industry

NEWARK, Calif., Feb. 12, 2024 /PRNewswire/ -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) for seladelpar, an investigational treatment for the management of primary biliary cholangitis (PBC) including pruritus in adults without cirrhosis or with compensated cirrhosis (Child Pugh A) who are inadequate responders or intolerant to ursodeoxycholic acid. The FDA has granted priority review and set a Prescription Drug User Fee Act (PDUFA) target action date of August 14, 2024 and notified the company that it is not currently planning to hold an advisory committee meeting to discuss the application.

Key Points: 
  • PBC is a rare, chronic condition that can lead to inflammation and eventually liver cirrhosis.
  • People living with PBC can also experience symptoms that significantly impact their quality of life such as pruritus (itch) and fatigue.
  • Seladelpar is an investigational, potent, selective, orally active PPARδ agonist, or delpar, in development for PBC treatment.
  • "We are encouraged by the agency's decision to grant priority review for seladelpar, and its recognition of the significant need for new treatment options for people living with PBC.